Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015)

Name: Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015) | Business Quant
Creator: Business Quant

Ocugen posted quarterly Long-Term Deferred Tax of $1.1 million for Q3 2015, up 0.86% on a QoQ basis from $1.0 million in Q2 2015.

Ocugen (OCGN) has 2 years of Long-Term Deferred Tax data on file, last reported at $1.1 million in Q3 2015.

For the quarter ending Q3 2015, Long-Term Deferred Tax changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Sep 2015 stood at $1.1 million (changed N/A YoY), and the FY2014 full-year result was $651000.0, changed N/A from the prior year.
Long-Term Deferred Tax for Q3 2015 stood at $1.1 million, up from $1.0 million in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $1.1 million in Q3 2015 and bottomed at $651000.0 in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	1,216,509.61 Bn	1,216,509.61 Bn	-
2	Alterity Therapeutics	764,224.41 Bn	764,224.38 Bn	-
3	Legend Biotech	2,716.00 Bn	2,715.71 Bn	242.10 Mn
4	Nanobiotix	2,248.83 Bn	2,248.77 Bn	-
5	Akari Therapeutics	1,951.18 Bn	1,951.17 Bn	-
6	Vertex Pharmaceuticals	113.69 Bn	106.44 Bn	2.59 Bn
7	Evaxion A	64.16 Bn	64.14 Bn	-
8	Regeneron Pharmaceuticals	63.94 Bn	55.18 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	40.13 Bn	37.12 Bn	959.66 Mn
10	Ocugen	452.01 Mn	452.01 Mn	-

Download Data 🔒